US Stock Market Movement: Genmab Surges on October 5 Due to AbbVie Collaboration, EPKINLY Phase III Results, and Rina-S
Bitget异动解读2026/10/05 18:55Genmab Surges on October 5th: Analysis
Keywords: AbbVie collaboration, EPKINLY Phase III, Rina-S
1. On October 6th, Genmab and AbbVie announced that the Phase III trial of EPKINLY combined with R-CHOP for the treatment of newly diagnosed diffuse large B-cell lymphoma showed a statistically significant improvement in progression-free survival, with a 51% reduction in the risk of disease progression or death.
2. On October 3rd, Genmab released data from the RAINFOL-01 trial of Rina-S for the treatment of platinum-resistant ovarian cancer: among 109 patients, the confirmed objective response rate was 45.9%, including 5 complete responses, with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. Antitumor activity was observed regardless of FRα expression level and prior treatment with mirvetuximab.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Meta and Microsoft strive to reduce employees’ reliance on Claude: Meta’s internal usage has halved, and Microsoft has cut its budget by one-third.
Microsoft's internal Claude budget has been reduced by more than one-third from its peak, and the number of internal Claude Code users at Meta has dropped from around 60,000 to 30,000. Both companies emphasize that external customer demand is still growing, but the decline in internal usage puts pressure on Anthropic. According to Anthropic's IPO prospectus, two major clients together contributed about 25% of its revenue. Although the prospectus does not name specific clients, it is highly likely that Meta and Microsoft are these two clients or among them.
US Stock Market Movement: Charles River surged on October 5th, reaffirmed guidance, 2030 target, and CRO.
New York oil prices closed down 1.84%, Brent fell 1.89%
At the close of the day, the price of light crude oil futures for November delivery on the New York Mercantile Exchange fell by $1.68 to $89.43 per barrel, a decrease of 1.84%. The price of Brent crude oil futures for December delivery in London dropped by $1.93, settling at $100.32 per barrel, a decline of 1.89%.
Crypto prices
More
